Effect of Intranasal Administration of Lactobacillus casei Shirota on Influenza Virus Infection of Upper Respiratory Tract in Mice

TETSUJI HORI,* JUNKO KIYOSHIMA, KAN SHIDA, AND HISAKO YASUI

Yakult Central Institute for Microbiological Research, 1796 Yaho, Kunitachi, Tokyo 1868650, Japan

Received 29 December 2000/Returned for modification 16 February 2001/Accepted 12 March 2001

In mice administered Lactobacillus casei strain Shirota (LcS) intranasally, potent induction of interleukin 12, gamma interferon, and tumor necrosis factor alpha, which play a very important role in excluding influenza virus (IFV), was evident in mediastinal lymph node cells. In this model of upper respiratory IFV infection, the titers of virus in the nasal wash of mice inoculated with 200 μg of LcS for three consecutive days (LcS 200 group) before infection were significantly (P < 0.01) lower than those of mice not inoculated with LcS (control group) (1.0 ± 0.8 versus 102.1 ± 1.4). The IFV titer was decreased to about 1/10 of the control level. Using this infection model with modifications, we investigated whether the survival rate of mice was increased by intranasal administration of LcS. The survival rate of the mice in the LcS 200 group was significantly (P < 0.05) greater than that of the control mice (69% versus 15%). It seems that the decrease in the titer of virus in the upper respiratory tract to 1/10 of the control level was important in preventing death. These findings suggest that intranasal administration of LcS enhances cellular immunity in the respiratory tract and protects against influenza virus infection.

Influenza virus (IFV) infections continue to be a significant public health problem for which improved therapies and preventive treatments are urgently needed. Some of the therapeutic approaches used thus far have included antiviral compounds (9, 23), vaccines (10), and biological response modifiers (2, 8, 21). In recent years, there has been an increased tendency in modern medicine to apply preventive treatments involving the use of probiotics, such as Lactobacillus or Bifidobacterium.

A probiotic is defined by Havenaar (7) as a monoculture or mixed culture of living microorganisms that is applied to animals or man, beneficially affecting the host by improving the properties of the indigenous gastrointestinal microflora. It is restricted to products that contain living microorganisms, improve the health and well-being of man or animals, and can have an effect on all host mucosal surfaces, including the mouth, gastrointestinal tract (e.g., applied in food), upper respiratory tract (e.g., applied as an aerosol), or urogenital tract (local application). However, recently the definition of a probiotic has become even broader, and it has been concluded (local application) that dead bacteria and metabolic products with immunostimulatory activity or activity in prevention of infection by pathogens should be included in this category. Lactic acid bacteria and their products have been reported to have beneficial effects on host homeostasis and are effective in activating the immune system (4, 5).

Lactobacillus casei strain Shirota (LcS), a member of the lactic acid bacteria, was originally isolated from the human intestine and has been used commercially for a long time to produce fermented milk. Various aspects of the effects of LcS have been studied intensively. LcS exhibits remarkable activity against syngeneic and allogeneic tumors (12, 16) and against various pathogens, such as Pseudomonas aeruginosa and Listeria monocytogenes (18, 20). However, whether LcS exhibits activity against IFV has not been reported.

The purpose of the present study was to investigate the effects of intranasal administration of LcS on activation of the immune system in the respiratory tract and on IFV infection of the upper respiratory tract. Special attention was focused on the possibility of inhibiting IFV infection through intranasal administration of LcS.

MATERIALS AND METHODS

Mice. BALB/c female mice, 10 and 11 weeks old, were obtained from Japan SLC, Inc. (Hamamatsu-shi, Japan), and used for the experiments.

LcS. LcS was originally isolated from human feces at Yakult Central Institute for Microbiological Research (Tokyo, Japan). LcS cells were cultured for 24 h at 37°C in MRS medium (Difco Laboratories, Detroit, Mich.), collected by centrifugation, and washed several times with sterile distilled water. The LcS cells were killed by heating at 100°C for 30 min and lyophilized. The lyophilized preparation was suspended in saline and autoclaved (121°C, 20 min) before intranasal administration to mice. Mice received intranasal administration three times, i.e., 20 μl of LcS solution at a concentration of 0, 1, or 10 mg/ml (0, 20, or 200 μg per mouse) once daily for three consecutive days.

Virus. Influenza A/PR/8/34 (PR8, H1N1) virus was grown in the allantoic sacs of 11-day-old chicken embryos at 34°C for 2 days by the method of Yasui et al. (27). The allantoic fluid was removed and stored at −80°C. The titer of virus in the allantoic fluid was expressed as the 50% egg-infecting dose (EID50) (26). Serial 10-fold dilutions of the allantoic fluid were injected into embryonated eggs, and the presence of virus in the allantoic fluid of each egg was determined on the basis of the hemagglutinating capacity 2 days after injection. The titer of virus was 103.2 EID50/ml.

PR8 was purified from the allantoic fluid from 11-day-old embryonated eggs. The details of the procedure for purification of PR8 have been described previously (27).

Mediastinal lymph node cell culture. On the next day after completion of intranasal administration of the LcS solution at a concentration of 0 (control group), 1 (LcS 20 group), or 10 (LcS 200 group) mg/ml for three consecutive days, the mice were anesthetized with diethyl ether and killed by exsanguination.
Mediastinal lymph nodes (MLNs) were aseptically removed, and single-cell suspensions were prepared after depletion of erythrocytes. In experiment 1, 2.5 × 10^6 cells were cultured in the absence or presence of concanavalin A (ConA) (Sigma) at 2 μg/ml in 0.1 ml of RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum, 100 U of penicillin/ml, and 100 μg of streptomycin/ml in a 96-half-area-well culture plate (Corning, Corning, N.Y.). In experiment 2, 2.5 × 10^6 cells were cultured in the absence or presence of purified PR8 at doses ranging from 0.2 to 20 μg of protein/ml in 0.1 ml of RPMI containing 10% heat-inactivated fetal calf serum, 100 U of penicillin/ml, and 100 μg of streptomycin/ml in a 96-half-area-well culture plate. Supernatants were collected on day 5 for determination of cytokine concentrations and stored at −80°C for further analysis.

ELISA for determination of cytokine concentrations. Gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4), and IL-12 concentrations were determined by sandwich enzyme-linked immunosorbent assay (ELISA). IFN-γ, TNF-α, and IL-4 concentrations were measured using DuoSet mouse IFN-γ, TNF-α, and IL-4 ELISA kits (Genzyme), respectively, according to the recommended protocol. For measurement of IL-12 concentrations, rat anti-mouse IL-12 monoclonal antibody (C 15.6; Pharmingen) was used as the capture antibody and biotinylated rat anti-mouse IL-12 monoclonal antibody (clone C17.8; Pharmingen) was used as the detection antibody. Standard recombinant mouse IL-12 was purchased from Pharmingen.

Infection. On the next day after completion of intranasal administration of LcS solution at a concentration of 0, 1 or 10 mg/ml for three consecutive days, mice were anesthetized by intraperitoneal injection of sodium amobarbital (0.25 μg per mouse) (27), and then the mice were infected by dropping 1 ml of fluid containing 10^6 EID_50 of PR8 into each nostril (2 μl per mouse). Three days after inoculation, the titers of virus in the nasal wash were measured by the method of Tamura et al. (24). Thereafter, the mice were anesthetized with diethylether and killed by exsanguination. The head of each mouse was removed, and the posterior opening of the nasopharynx, and a total of 1 ml of phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin was injected. This procedure was repeated three times, and the outflow was collected each time as nasal wash. The nasal wash was centrifuged at 13,000 × g to remove cellular debris and used for virus titration. The titer of virus in each experimental group is expressed as the mean ± the standard deviation (SD) of the viral titer of each wash specimen from all mice in each group.

To examine the survival of mice inoculated with PR8 solution, PBS was administered intranasally 3 days after inoculation of the mice with PR8. After nasal inoculation with PR8, the mice were monitored for 14 days to assess the survival rate.

Statistical analyses. Cytokine concentrations were compared by means of Student’s t test and Dunnett’s test. The differences in titers of virus in the nasal wash were examined by means of Dunnett’s test. The differences in survival rates were examined by means of Fisher’s exact test. Probability values of less than 5% were considered significant.

RESULTS

Effect of intranasal administration of LcS on production of various cytokines by MLN cells. In experiment 1, we investigated the effect of intranasal administration of LcS on production of various cytokines by MLN cells (Fig. 1). When the cells were cultured in the absence of ConA, no significant differences in the concentrations of IFN-γ, TNF-α, or IL-4 (Fig. 1B, C, and D) were observed, but the concentrations of IL-12 were significantly (P < 0.01) different (Fig. 1A). The IL-12 concentrations in the case of the LcS 200 group and the control group were 970 ± 35 and 400 ± 130 pg/ml, respectively. The mean IL-12 concentration in the case of the LcS 200 group was about 2.5 times higher than that for the control group.

In the next study, we measured production of various cytokines by MLN cells stimulated with ConA, which was T-cell mitogen, to prove the activation of T cells by intranasal administration of LcS (Fig. 1). The concentrations of IL-12, TNF-α, and IL-4 were not significantly different among the three groups (Fig. 1A, C, and D). However, the IFN-γ concentration in the case of the LcS 200 group was significantly (P < 0.01) different from that for the control group (Fig. 1B). The IFN-γ concentrations in the case of the LcS 200 and control groups were 1,180 ± 220 and 510 ± 160 pg/ml, respectively. The concentrations of IL-12, IFN-γ, TNF-α, and IL-4 in

FIG. 1. Effect of intranasal administration of LcS to mice on production of IL-12, IFN-γ, TNF-α and IL-4 by MLN cells. MLN cells from mice administered LcS 0 (control) (◼), LcS 20 (●), or LcS 200 (▲) intranasally were cultured in the absence (−) or presence (+) of ConA. Supernatants were collected 72 h after the initiation of culture, and the concentrations of various cytokines were determined. Each bar represents the mean ± SD of triplicate samples. Double asterisk, statistically significant difference from the control by Dunnett’s test at P < 0.01.
the case of the LcS 20 group were not different from those for the control group.

**Effect of intranasal administration of LcS on production of various cytokines by MLN cells cultured in the presence of PR8.** In experiment 2, we investigated the effect of intranasal administration of LcS on production of various cytokines by MLN cells stimulated with purified PR8. MLN cells from mice administered LcS 0 (control) or LcS 200 intranasally were cultured in the absence (0 μg/ml) or presence of purified PR8 (0.2 to 20 μg of protein/ml). Collection of supernatants and determination of various cytokines were performed in the same manner as described in the legend to Fig. 1. Each bar represents the mean ± SD of triplicate samples. Single, double, and triple asterisk, statistically significant difference from the control by Student’s t test at P < 0.05, P < 0.01, and P < 0.001, respectively.

![Figure 2](http://cvi.asm.org/)

**FIG. 2.** Effect of intranasal administration of LcS to mice on production of IL-12, IFN-γ, TNF-α, and IL-4 by MLN cells stimulated with purified PR8. MLN cells from mice administered LcS 0 (control) or LcS 200 intranasally were cultured in the absence (0 μg/ml) or presence of purified PR8 (0.2 to 20 μg of protein/ml). Collection of supernatants and determination of various cytokines were performed in the same manner as described in the legend to Fig. 1. Each bar represents the mean ± SD of triplicate samples. Single, double, and triple asterisk, statistically significant difference from the control by Student’s t test at P < 0.05, P < 0.01, and P < 0.001, respectively.

![Figure 3](http://cvi.asm.org/)

**FIG. 3.** Effect of intranasal administration of LcS on the titer of virus in nasal washes. Mice were administered 20 μl of LcS solution at the concentration of 0 (control), 1 (LcS 20), or 10 (LcS 200) mg/ml intranasally for three consecutive days. One day thereafter, the mice were intranasally infected with PR8, and 3 days later the titers of virus in the nasal washes from the infected mice were measured. Each bar represents the mean of values for 14 mice. Double asterisk, statistically significant difference from values for the control by Dunnett’s test at P < 0.01.
administration of LcS affects the survival rate of mice infected with PR8, using the above-described PBS-treated model. The survival rates of the mice in the control and LcS 200 groups were 15 and 69%, respectively (Fig. 5), and the difference was statistically significant ($P < 0.05$). It was found that intranasal administration of LcS protected against death due to IFV infection.

**DISCUSSION**

Recently it was reported that intranasal administration of *Lactobacillus fermentum* is effective in augmenting the respiratory immune system, especially through activation of macrophages (3). It was previously reported that LcS activates macrophages (18), NK cells (13), and cytotoxic T cells (14) and that activation of these cells contributes to antitumor and antibacterial activities. However, whether intranasal administration of LcS augments the respiratory immune system has not been reported. Therefore, we investigated this possibility and further examined whether antiviral activity was exhibited against IFV in mice.

It has been reported that MLN cells in the respiratory tract play an important role in preventing IFV infection (1, 6). Therefore, we investigated the production of various cytokines by MLN cells in mice administered LcS intranasally. It was found that the LcS administered intranasally strongly induced production of IL-12 in these cells. IL-12 is an important cytokine for cellular immunity. IL-12 potently stimulates cytotoxic T cells and NK cells and enhances the production of Th1 cytokines and the proliferation of Th1 cells. Shida et al. reported that LcS induces IL-12 production in splenocytes cultured in vitro (22). IL-12 is secreted by B cells, dendritic cells, and macrophages. Kato et al. reported that LcS activates X-ray-irradiated splenocytes, probably macrophages, and that these cells secreted IL-12 (15). It has been found in analysis of MLN cells from mice administered LcS intranasally that production not only of IL-12 but also of IFN-$\gamma$ and TNF-$\alpha$ is induced upon addition of purified PR8 to the culture. These results obtained in vitro are very interesting, because they resemble the cytokine response observed in cases of IFV infection in vivo. IL-12, IFN-$\gamma$, and TNF-$\alpha$ are thought to play a very important role in preventing IFV infection. IFN-$\gamma$ is produced by T cells, NK cells, and macrophages, and it has pleiotropic effects on various cells of the immune system. TNF-$\alpha$ is produced mainly by macrophages, and it has multiple effects of importance in terms of inflammation and immune functions. It has been reported that IL-12, IFN-$\gamma$, and TNF-$\alpha$ inhibit virus replication and are associated with protection against viral infection (11, 19, 25). In further studies, we are about to investigate whether these cytokines are produced in respiratory sites in mice administered LcS and infected with IFV and whether they inhibit IFV replication.

In elderly humans and in infants with low-level immune functions, IFV replicates in the upper respiratory tract and easily moves to the lower respiratory tract, and it frequently causes pneumonia. We tried to establish a murine model of IFV infection in which virus moves from the upper respiratory tract to the lower respiratory tract, and we used this model to study the effect of LcS. When mice were administered PBS intranasally 3 days after intranasal inoculation with IFV, the mortality rate for the mice was increased. Administration of PBS into the respiratory tract apparently enhanced viral spread to the lower respiratory tract and increased pulmonary damage, and as a result, it increased the mortality rate. Intranasal administration of LcS before inoculation of the mice with IFV resulted in a decrease in the mortality rate of the mice infected with IFV in the upper respiratory tract. A decrease in the titer of IFV in the upper respiratory tract is a very important phenomenon. In the mice administered LcS, the titer of IFV decreased to 1/10 of that in the control group, and this was a key point in preventing death of the host. It seems that intranasal administration of LcS augmented cellular immunity in the respiratory tract and decreased the titer of virus in the nasal wash, and as a result, the survival rate of the mice was increased.

Cangemi de Gutierrez et al. have reported that intranasal administration of *L. fermentum* activates macrophages in the respiratory tract of mice (3). No other reports on protection against respiratory infection by intranasal administration of

---

**FIG. 4.** Survival of mice infected with PR8 in the upper respiratory tract. Mice were inoculated with 2 $\mu$l of fluid containing $10^{3.5}$ EID$_{50}$ of PR8, and PBS was administered intranasally at 3 days postinfection ($n = 8$) ($\triangle$). Infected mice not administered PBS intranasally served as controls ($n = 6$) ($\blacksquare$). After nasal inoculation with PR8, the mice were observed for 14 days to assess the survival rates. Double asterisk, statistically significant difference from the control by Fisher’s exact test at $P < 0.01$.

**FIG. 5.** Protection against mortality due to IFV infection in mice administered LcS intranasally. Mice administered LcS ($\bullet$) ($n = 13$) intranasally and mice not administered LcS ($\bigtriangleup$) ($n = 13$) were inoculated with 2 $\mu$l of fluid containing $10^{3.5}$ EID$_{50}$ of PR8, and PBS was administered intranasally at 3 days postinfection. Assessment of the survival was performed in the same manner as described in the legend to Fig. 4. Asterisk, statistically significant difference from the control by Fisher’s exact test at $P < 0.05$. 

---

*HORI ET AL.* CLIN. DIAGN. LAB. IMMUNOL.
probiotics have yet been published. In this paper, we demonstrate that intranasal administration of LcS activates cellular immunity in the respiratory tract and protected against IFV infection.

Since LcS is used to produce fermented milk and is safe, it may be useful to apply LcS as an aerosol or spray to prevent respiratory infections. In a preliminary experiment, polysaccharide-peptidoglycan, one component of LcS that was reported to possess antitumor activity (17), was found to be protective against IFV infection (unpublished data). It seems possible that the active constituents of LcS may include polysaccharide-peptidoglycan.

We have been studying two strains of lactic acid bacteria which modulated the different immune systems each in its own way (28). One strain was *Bifidobacterium breve* YIT 4064, which enhanced humoral immunity. We have previously reported that oral administration of this strain augmented production of antigen-specific immunoglobulin G in the serum and protected against IFV infection in mice (27). The other strain was LcS, which enhanced cellular immunity, inhibited the growth of tumors, and protected against bacterial infection. In this study, we examined whether intranasal administration of LcS activated cellular immunity in the respiratory immune system and protected against IFV infection. We are now studying whether oral administration of LcS activates the cellular immune system in the respiratory tract and whether this leads to effective protection against IFV infection.

ACKNOWLEDGMENTS

We thank S. Tamura, H. Asanuma, and T. Kurata (National Institute of Health, Tokyo, Japan) for help with the study and M. Watanuki for helpful discussions.

REFERENCES

1. Allan, W., Z. Tabi, A. Cleary, and P. C. Doherty. 1990. Cellular events in the lymph node and lung of mice with influenza. J. Immunol. 144:3980–3986.
2. Bertagnolli, M. M., B. Y. Lin, D. Young, and S. H. Herrmann. 1992. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J. Immunol. 149:3778–3783.
3. Cangemi de Gutierrez, R., V. Santos de Araoz, and M. E. Nader-Macias. 2000. Effect of intranasal administration of *Lactobacillus fermentum* on the respiratory tract of mice. Biol. Pharm. Bull. 23:973–978.
4. Fernandes, C. F., and K. M. Shahani. 1990. Anticarcinogenic and immunological properties of dietary lactobacilli. J. Food Prot. 53:704–710.
5. Gilliland, S. E. 1989. Acidophilus milk products: a review of potential benefits to consumers. J. Dairy Sci. 72:2483–2494.
6. Hamilton-Easton, A., and M. Eichelberger. 1995. Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice. J. Virol. 69:6359–6366.
7. Havenaar, R., T. Brinck, and J. H. Huis in't Veld. 1992. Selection of strains for probiotic use, p. 209–224. In R. Fuller (ed.), Probiotics: the scientific basis. Chapman & Hall, London, England.
8. Hennet, T., H. J. Ziltener, K. Frei, and E. Peterhans. 1992. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J. Immunol. 149:932–939.
9. Herrmann, J. E., M. Bruns, K. West, and F. A. Ennis. 1989. Efficacy of rimantadine hydrochloride in the treatment of influenza infection of mice. Antivir. Res. 11:127–135.
10. Inuma, H., K. Kerome, Y. Yoshioka, and K. Okinaga. 1995. Characteristics of cytotoxic T lymphocytes directed to influenza-virus hemagglutinin elicited by immunization with muramyldipeptide-influenza-liposome vaccine. Scand. J. Immunol. 41:1–10.
11. Karupiah, G., Q. Xie, R. M. L. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. 1993. Inhibition of viral replication by interferon-γ induced nitric oxide synthase. Science 261:1445–1448.
12. Kato, I., S. Kobayashi, T. Yokokura, and M. Mutai. 1981. Antitumor activity of *Lactobacillus casei* in mice. Gann 72:517–523.
13. Kato, I., T. Yokokura, and M. Mutai. 1984. Augmentation of mouse natural killer cell activity by *Lactobacillus casei* and its surface antigens. Microbiol. Immunol. 27:209–217.
14. Kato, I., T. Yokokura, and M. Mutai. 1988. Correlation between increase in IgA-bearing macrophages and induction of T-cell-dependent anti-tumor activity by *Lactobacillus casei* in mice. Cancer Immunol. Immunother. 26:215–221.
15. Kato, I., K. Tunaka, and T. Yokokura. 1999. Lactic acids bacterium potently induces the production of interleukin-12 and interferon-γ by mouse splenocytes. Int. J. Immunopharmacol. 21:121–131.
16. Matsuuzaki, T., T. Yokokura, and M. Mutai. 1988. Antitumor effect of intraperitoneal administration of *Lactobacillus casei* in mice. Infect. Immun. 48:209–214.
17. Matsuuzaki, T., N. Nagaoaka, K. Nomoto, and T. Yokokura. 1990. Antitumor effect of polysaccharide-peptidoglycan complex (PS-PG) of *Lactobacillus casei* YIT 9018 on Meth A. Jpn. Pharmacol. Ther. 185:31–57.
18. Miake, S., T. Yokokura, Y. Yoshikai, M. Mutai, and K. Nomoto. 1985. Protective effect of *Lactobacillus casei* on *Pseudomonas aeruginosa* infection in mice. Infect. Immun. 48:480–485.
19. Monteiro, J. M., C. Harvey, and G. Trinchieri. 1998. Role of interleukin-12 in primary influenza virus infection. J. Virol. 72:4825–4831.
20. Nomoto, K., S. Miake, S. Hashimoto, T. Yokokura, M. Mutai, Y. Yoshikai, and K. Nomoto. 1985. Augmentation of host resistance to *Listeria monocytogenes* infection by *Lactobacillus casei*. J. Clin. Lab. Immunol. 17:91–97.
21. Sarawar, S. R., M. Sanger, R. L. Coffman, and P. C. Doherty. 1994. Administration of anti-IFN-gamma antibody to beta 2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a Th helper cell 2 phenotype. J. Immunol. 153:1246–1253.
22. Shida, K., K. Makino, A. Morishita, K. Takamizawa, S. Hachimura, A. Amitani, T. Sato, Y. Kumagai, S. Habu, and S. Kaminogawa. 1998. *Lactobacillus casei* inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. Int. Arch. Allergy Immunol. 115:278–287.
23. Sidwell, R. W., J. H. Huffman, E. W. Call, H. Alaghamandand, P. D. Cook, and R. K. Robins. 1986. Effect of selenoazofuran on influenza A and B virus infections of mice. Antivir. Res. 6:343–353.
24. Tamura, S., K. Miyata, K. Matsuo, H. Asanuma, H. Takahashi, K. Nakajima, Y. Suzuki, T. Mizutani, and K. Nomoto. 1996. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156:3892–3900.
25. Van Campen, H. 1994. Influenza A virus replication is inhibited by tumor necrosis factor-α in vitro. Arch. Virol. 136:39–44.
26. Webster, R. G., and B. A. Askonas. 1980. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur. J. Immunol. 10:396–401.
27. Yasui, H., J. Kiyoshima, T. Hori, and K. Shida. 1999. Protection against influenza virus infection of mice fed *Bifidobacterium breve* YIT 4064. Clin. Diagn. Lab. Immunol. 6:186–192.
28. Yasui, H., K. Shida, T. Matsuzaki, and T. Yokokura. 1999. Immunomodulatory function of acid lactic bacteria. Antonie Leeuwenhoek 76:383–389.